Kiniksa Pharmaceuticals International, plc (KNSA)

Market Cap	2.05B
Revenue (ttm)	481.17M
Net Income (ttm)	-16.95M
Shares Out	72.97M
EPS (ttm)	-0.24
PE Ratio	n/a
Forward PE	25.97
Dividend	n/a
Ex-Dividend Date	n/a

Volume	355,269
Open	28.51
Previous Close	28.95
Day's Range	27.95 - 28.51
52-Week Range	17.82 - 30.69
Beta	0.05
Analysts	Strong Buy
Price Target	39.33 (+40.11%)
Earnings Date	Jul 22, 2025

About KNSA

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, developing and commercializing novel therapies for diseases with unmet need and focuses on cardiovascular indications worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-387, an in...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: May 24, 2018
• Employees: 315
• Stock Exchange: NASDAQ
• Ticker Symbol: KNSA
• Website: https://www.kiniksa.com

Analyst Summary

According to 6 analysts, the average rating for KNSA stock is "Strong Buy." The 12-month stock price target is $39.33, which is an increase of 40.11% from the latest price.

Price Target

$39.33

(40.11% upside)

Analyst Consensus: Strong Buy